Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
TRYPF TRYP THERAPEUTICS INC
0.0710.0000.00%
Trading Session
01/31 09:30 ET
High
0.000
Open
0.000
Turnover
0.00
Low
0.000
Pre Close
0.071
Volume
0.00
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Rising High: Exclusive Talk With Biotech Company Tryp Therapeutics
Treating Binge Eating Disorder With Magic Mushrooms: Phase 2 Clinical Trial Gets Thumbs Up
Clinical-stage psychedelics biotech Tryp Therapeutics, Inc. (OTCQB:TRYPF) shared the interim results for the first five patients dosed in its Phase 2 STOP (Study of the Treatment of Overeating utilizi
Tryp Therapeutics Announces Interim Results for Its Phase II Clinical Trial for the Treatment of Binge Eating Disorder With Psilocybin-Assisted Psychotherapy
Interim data analysis supports the potential effectiveness of psilocybin-assisted psychotherapy for the treatment of Binge Eating DisorderTRP-8802 demonstrated significant and prolonged improvement in
Business & Academia Join Forces To Study Magic Mushroom Therapy For IBS Patients
Psychedelics company Tryp Therapeutics Inc. (OTCQB:TRYPF) and Harvard's largest medical teaching facility, the Massachusetts General Hospital (MGH) have inked a Letter of Intent (LOI) to fund and cond
Tryp Therapeutics and Massachusetts General Hospital Sign Letter of Intent for Clinical Study Investigating the Use of Psilocybin-Assisted Psychotherapy for the Treatment of Patients Suffering From Irritable Bowel Syndrome (IBS)
KELOWNA, BC / ACCESSWIRE / January 3, 2023 / Tryp Therapeutics, Inc. (CSE:TRYP) (OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing intravenous-infuse
Tryp Therapeutics to Present at Biotech Showcase on Monday, January 9, 2023
Company to be in San Francisco January 8-11, 2023, during 41st Annual J.P. Morgan Health Care ConferenceKELOWNA, British Columbia, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE: TRY
Tryp Therapeutics GAAP EPS of -C$0.10
Tryp Therapeutics Announces Fiscal Year 2022 Financial Results and Reports Corporate Highlights
KELOWNA, British Columbia, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE:TRYP) (OTCQB:TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active
Tryp Therapeutics Announces Poster Presentations at SfN Conference
Tryp Therapeutics Announces Poster Presentations on the Reduction of Chronic Pain in a Rodent Model With Psilocybin and Intravenous Psilocybin Alters Brain Network Dynamics in Rats at the 2022 Society for Neuroscience Conference
KELOWNA, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developin
Company Overview
More
Tryp Therapeutics, Inc. is a pharmaceutical company, which engages in identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs. The company was founded on September 24, 2019 and is headquartered in Kelowna, Canada.
CEO： --
Market： Pink Market
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet